Xiaokun Xiao
Overview
Explore the profile of Xiaokun Xiao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
909
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim Y, Jo M, Schmidt J, Luo X, Prakash T, Zhou T, et al.
Mol Ther
. 2019 Jul;
27(9):1547-1557.
PMID: 31303442
Antisense oligonucleotides (ASOs) are a novel therapeutic approach to target difficult-to-drug protein classes by targeting their corresponding mRNAs. Significantly enhanced ASO activity has been achieved by the targeted delivery of...
2.
Reilley M, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, et al.
J Immunother Cancer
. 2018 Nov;
6(1):119.
PMID: 30446007
Background: The Janus kinase (JAK) and signal transduction and activation of transcription (STAT) signaling pathway is an attractive target in multiple cancers. Activation of the JAK-STAT pathway is important in...
3.
Paz S, Hsiao J, Cauntay P, Soriano A, Bai L, Machemer T, et al.
Nucleic Acid Ther
. 2017 Jun;
27(5):272-284.
PMID: 28605247
Antisense oligonucleotides (ASOs) are widely accepted therapeutic agents that suppress RNA transcription. While the majority of ASOs are well tolerated in vivo, few sequences trigger inflammatory responses in absence of...
4.
Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, et al.
Sci Transl Med
. 2015 Nov;
7(314):314ra185.
PMID: 26582900
Next-generation sequencing technologies have greatly expanded our understanding of cancer genetics. Antisense technology is an attractive platform with the potential to translate these advances into improved cancer therapeutics, because antisense...
5.
Hung G, Xiao X, Peralta R, Bhattacharjee G, Murray S, Norris D, et al.
Nucleic Acid Ther
. 2013 Oct;
23(6):369-78.
PMID: 24161045
Advances in the medicinal chemistry of antisense oligonucleotide drugs have been instrumental in achieving and optimizing antisense activity in cell types other than hepatocytes, the cell type that is most...
6.
Zhang B, Arun G, Mao Y, Lazar Z, Hung G, Bhattacharjee G, et al.
Cell Rep
. 2012 Jul;
2(1):111-23.
PMID: 22840402
Genome-wide studies have identified thousands of long noncoding RNAs (lncRNAs) lacking protein-coding capacity. However, most lncRNAs are expressed at a very low level, and in most cases there is no...
7.
Kim Y, Yoon J, Xiao X, Dean N, Monia B, Marcusson E
Cancer Res
. 2007 Apr;
67(8):3583-93.
PMID: 17440069
The sonic hedgehog (Shh) pathway contributes to the initiation and progression of tumors with various origins when aberrantly activated. In this study, we investigated if the Shh pathway is important...
8.
Koller E, Propp S, Zhang H, Zhao C, Xiao X, Chang M, et al.
Cancer Res
. 2006 Feb;
66(4):2059-66.
PMID: 16489005
A library of 2'-methoxyethyl-modified antisense oligonucleotides (2'MOE ASO) targeting 1,510 different genes has been developed, validated, and used to identify cell cycle regulatory genes. The most effective molecular target identified...